Precision BioSciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. (DTIL) on November 6, 2021. The report details corporate governance changes, specifically the appointment of two new directors to the Board of Directors, effective November 8, 2021.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
The Board of Directors appointed the following individuals:
- Samuel Wadsworth, Ph.D.: Appointed as a Class II director and member of the Science and Technology Committee. His term expires at the 2024 annual meeting.
- Shari Lisa Piré: Appointed as a Class III director and member of the Nominating and Corporate Governance Committee. Her term expires at the 2022 annual meeting.
Compensation and Governance Details
Both directors are eligible for the Non-Employee Director Compensation Program, which includes:
- Annual Cash Retainer: $40,000 for Board service, earned quarterly.
- Initial Equity Award: Options with an aggregate grant date fair value of $350,000, vesting over 36 months.
- Annual Equity Award: Options with an aggregate grant date fair value of $175,000, granted at the annual meeting (subject to service requirements).
- Committee Retainers: Dr. Wadsworth receives an additional $6,000 annually for the Science & Technology Committee; Ms. Piré receives an additional $4,500 annually for the Nominating and Corporate Governance Committee.
Both directors are expected to enter into the Company's standard form indemnification agreement.
Investor Verification Checklist
- Verify the effective date of the new directors' terms (November 8, 2021).
- Confirm the specific vesting schedules for the $350,000 initial equity awards.
- Review the press release (Exhibit 99.1) for additional biographical details on the new directors.
- Note that this filing does not contain updated financial results or operational guidance.